Shearwater Health Earns Great Place to Work® Certification Across U.S., Philippines, and India, Showcasing a Unified Commitment to Employee Well-Being Shearwater Health, a global leader in clinician-led clinical solutions, has…
Edgewood Oncology Unveils Compelling Preclinical Data Supporting BTX-A51 in Liposarcoma at AACR Annual Meeting 2025 Edgewood Oncology, a clinical-stage biotechnology company dedicated to advancing targeted cancer therapies, today announced new…
Mythic Therapeutics Presents Promising Preclinical Data Demonstrating Broad Antitumor Efficacy of MYTX-011 at the 2025 AACR Annual Meeting Mythic Therapeutics, a clinical-stage biotechnology company pioneering the next generation of antibody-drug…
Puma Biotechnology Showcases Promising Neratinib Combination Data at AACR Annual Meeting 2025 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company specializing in the development of innovative cancer treatments, has presented…
Agenus Presents Promising BOT/BAL Neoadjuvant Pan-Cancer Data from NEOASIS Study at AACR Annual Meeting Agenus Inc. (Nasdaq: AGEN), a clinical-stage immuno-oncology company focused on developing therapies designed to activate the…
LEAP Consulting Group Accelerates Clinical Lab Digital Transformation with Appointment of Dr. Heather E. Williams as Practice Principal, Life Sciences LEAP Consulting Group, a boutique digital consultancy recognized for its…
Fellow Health to Present Groundbreaking Research on Prostate Cancer Biomarkers and Mail-In PVSA Testing at AUA 2025 Fellow Health, a pioneering healthcare company dedicated to advancing male reproductive health through…
Dyno Therapeutics to Present Cutting-Edge AAV Gene Delivery Data for CNS, Eye, and Muscle at 2025 ASGCT Annual Meeting Dyno Therapeutics, Inc., a pioneer in genetic technologies harnessing the power…
Obsidian Therapeutics to Present Groundbreaking Preclinical Data on cytoDRiVE® Platform at the 2025 ASGCT Annual Meeting Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches to cell and gene…
Sangamo Therapeutics to Highlight Neurology Pipeline Innovations with Nine Presentations at 28th ASGCT Annual Meeting Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company focused on developing transformative therapies for…
Strand Therapeutics Unveils Groundbreaking Preclinical Data for STX-003, a Programmable mRNA Therapy Targeting Solid Tumors Strand Therapeutics Inc., a biotechnology company pioneering programmable mRNA technology to develop curative therapies for…
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage biotechnology company committed to developing transformative genetic medicines for patients and families affected by rare neurological diseases, has announced its upcoming participation in the…